Oncogenic PI3K and its role in cancer

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 77-82

  Samuels, Yardena ^a   Ericson, Kajsa ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Oncogene; p110 ; PI3K pathway; PIK3CA

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

CANCER; CARCINOGENESIS; CATALYST; COLORECTAL CANCER; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBUNIT; GENE MUTATION; GENETIC ANALYSIS; HUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 33646706052     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198021.99347.b9     Document Type: Review

References (61)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-1657.
3. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:13375-13378.
4. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
5. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
6. Rohrschneider LR, Fuller JF, Wolf I, et al. Structure, function, and biology of SHIP proteins. Genes Dev 2000; 14:505-520.
7. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615-675.
8. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
9. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772-775.
10. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64:5048-5050.
11. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64:7678-7681.
12. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005; 102:802-807.
13. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7:561-573.
14. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65:4562-4567.
15. Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997; 276:1848-1850.
16. Staal SP, Hartley JW. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med 1988; 167:1259-1264.
17. Aoki M, Batista O, Bellacosa A, et al. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A 1998; 95:14950-14955.
18. Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19:348-355.
19. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999; 96: 1563-1568.
20. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8:1169-1178.
21. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
22. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-2963.
23. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 1987; 84:5034-5037.
24. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64:280-285.
25. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992; 89:9267-9271.
26. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996; 93:3636-3641.
27. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102.
28. Actor B, Cobbers JM, Buschges R, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 2002; 34:416-427.
29. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003; 13:507-518.
30. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61:7426-7429.
31. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 3:113-117.
32. Hartmann C, Bartels G, Gehlhaar C, et al. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol (Berl) 2005; 109:639-642.
33. Li VS, Wong CW, Chan TL, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5:29.
34. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24:1477-1480.
35. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-2559.
36. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005; 11:2875-2878.
37. Wu G, Xing M, Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7:R609-R616.
38. Wang Y, Heiland A, Holm R, et al. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005; 25:322.
39. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787-1790.
40. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Research 1998; 58:1130-1134.
41. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
42. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.
43. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436:792.
44. Sun H, Lesche R, Li DM, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1999; 96:6199-6204.
45. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000; 7:115-129.
46. Aoki M, Schetter C, Himly M, et al. The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem 2000; 275:6267-6275.
47. Mende I, Malstrom S, Tsichlis PN, et al. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001; 20:4419-4423.
48. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13:2905-2927.
49. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-297.
50. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9:59-71.
51. Dufour G, Demers MJ, Gagne D, et al. Human intestinal epithelial cell survival and anoikis: differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms. J Biol Chem 2004; 279:44113-44122.
52. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001; 15:2203-2208.
53. Stiles B, Gilman V, Khanzenzon N, et al. Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 2002; 22:3842-3851.
54. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280:1614-1617.
55. Tamura M, Gu J, Takino T, et al. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999; 59:442-449.
56. Kim D, Kim S, Koh H, et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J 2001; 15:1953-1962.
57. Park BK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 2001; 61:7647-7653.
58. Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41:161-170.
59. Suzuki A, Lu J, Kusakai G, et al. ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 2004; 24:3526-3535.
60. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 2003; 73:689-701.
61. Kang S, Bader AG, Zhao L, et al. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 2005; 4:578-581.